HRAS and breast cancer: This study has shown both TERT promoter and HRAS oncogenic variants in all six BC specimens from four different patients, but not in benign oral mucosal, non-cancerous PVL lesions or CSCC samples tested, suggesting these recurrent genomic changes are probably common or potentially even characteristic in BC.